• Founded: 2017
  • Location: Durham, NC
  • Employee range: 50 - 200
  • Clinical stage: Clin0
  • Therapy area: Friedreich's ataxia
  • Drug types: RAR, NEU, PED, GEN, CVV
  • Lead product: STRX-110
  • Product link:
  • Funding: $48M partnership Nov 2019; $15.7M A Jun 2018

job board

Short description:

Antibody-Evading Gene Therapy

Drug notes:

STRX-330 Clin0 ventricular cardiomyopathy; STRX-210 Clin0 Niemann Pick type C; STRX-230 Clin0 Rett syndrome; STRX-340 RD cardiomyopathy; STRX-220 RD Angelman syndrome; STRX-240 RD Dravet syndrome

Long description:

StrideBio is pioneering gene therapy technology to treat genetic diseases using adeno-associated viruses (AAVs). AAVs deliver DNA to target cells by packaging the DNA within a capsid. StrideBio is using their STRIVE Capsid platform, a differentiated discovery engine, to develop capsids with improved functionalities such as better safety profiles and easy manufacturing. The platform is driven by 3D capsid structures and improved functionalities are multiplexed onto single capsids. This enables StrideBio to expand their capsid arsenal and IP estate, both of which StrideBio will use for therapeutic translation. StrideBio’s lead candidate, ARVC, is due to start clinical trials soon and is, along with their remaining internal pipeline, focused on cardiovascular indications.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy